NEW YORK (GenomeWeb) – Genomic Health said today that it has signed a multi-year research collaboration agreement with Janssen Pharmaceuticals in which the companies will evaluate Genomic Health’s Oncotype DX Genomic Prostate Score as a predictor of response to prostate cancer drugs in Janssen’s pipeline.
Under the terms of the agreement, Genomic Health will test samples from studies Janssen is conducting to examine the association of GPS results with clinical outcomes.
The Oncotype Dx GPS test provides a genomically derived score of a tumor’s aggressiveness that can help doctors decide on more conservative versus more aggressive management. National Medicare contractor Palmetto GBA issued a favorable final local coverage determination in August, expanding coverage of the test from clinically low-risk patients to those considered to be at intermediate risk as well.
In addition to the deal with Janssen, Genomic Health also said today that it has made a $4 million equity investment in Biocartis as part of the two companies’ partnership to develop an in vitro diagnostic version of the Oncotype DX Breast Recurrence Score test on Biocartis’ Idylla platform.